Tianjin Meihua Pharmaceutical Co., Ltd. was established in March 2011, located in the West District of Tianjin Development Zone, covering an area of 50 acres with a total investment of 300 million yuan. It is a high-tech enterprise engaged in drug research and development, production, and sales. The company has advanced experimental instruments and production equipment, as well as a group of professional technical talents in new drug research. They have a high level of expertise in the development of respiratory drug varieties, slow and controlled release technology, masking technology for drug formulations, and plant medicine extraction. The company mainly focuses on the research and production of respiratory system drugs and sustained-release formulations. Having GMP A drug with GSP qualification certification and multiple drug variety production approvals and national approval numbers. At present, the company has independently developed respiratory commonly used drugs, mainly "injectable Doxophylline" and "ambroxol hydrochloride injection", and the related technologies have applied for multiple invention patents; The sustained-release technology represented by "Gliclazide sustained-release capsules" has reached the leading level in China. At the same time, in recent years, we have continuously increased international exchanges and established strategic cooperation with multiple Indian multinational pharmaceutical companies, committed to seeking greater development in the field of respiratory science.